Poster-Disease-modifying Therapy
October 25, 2021
Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls
Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab
Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of COVID-19 in people with...